First-in-Class Gene Editing Platform

Primera Therapeutics is focused on addressing the root cause of mitochondrial diseases by developing a first-in-class gene editing platform to target inherited mutant mitochondrial DNA. Primera’s leading approach uses a fully customizable TALE-based system linked to unique DNA modifying enzymes to specifically target the mutant DNA in the mitochondrial genome. This delivery application enables precision non-destructive gene editing to be deployed at the mitochondrial level for the first time. By leveraging an innovative toolbox with the support of key strategic partners, Primera seeks to accelerate the development of mitochondrial disease therapeutics and rapidly support this underserved patient population.